×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Disclaimer
Articles
Understanding Obesity: Beyond the Scale
What the 2025 Diabetes Care Updates Mean for You
Continuous Glucose Monitoring: A Game Changer for Type 2 Diabetes Management
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Public Perception of Obesity and Weight-Loss Drugs
Dexcom's Stelo: A New Era for Type 2 Diabetes Management
Denmark's AI Supercomputer: A Leap Forward in Tackling Type 2 Diabetes and Obesity
FDA Clears Dexcom's Stelo, First Over-the-Counter Glucose Biosensor for Type 2 Diabetes Management
Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Wegovy: A New Horizon in Cardiovascular Risk Reduction for Obesity
The Dual Roles of GLP-1 and GLP-2 in Metabolic Health
FDA Approves Lilly's Tirzepatide for Obesity
New York Takes a Bold Step to Tackle Insulin Affordability
Managing Blood Sugar with GLP-1 Medications: Foods to Avoid and Healthier Alternatives
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Subtle Yet Significant Changes: The 2024 ADA Standards of Care in Diabetes
How Well Do My CGM and BGM Readings Match?
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
September 2025
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
August 2025
FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Top Subjects
Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
